Fondazione Italiana Fegato develops antibodies to target tumor drug resistance

The SANDA project, part of the Booster for Life Science FVG program, is nearing completion after more than a year of experimental activity. The project focuses on developing new antibodies designed to target markers associated with drug resistance in tumors.

Devis Pascut, a senior scientist at the Fondazione Italiana Fegato (FIF), noted that these antibodies serve two primary roles in oncology: as tools in pathology laboratories to recognize specific molecules in tumor tissues for disease characterization, and as potential therapeutic drugs.

In the SANDA project, the Fondazione Italiana Fegato has specifically worked on developing two antibodies intended for research into the classification of patients with liver tumors. These tools aim to identify specific markers in tumor tissue that indicate how a patient might respond to certain treatments, helping to address the challenge of biological differences in tumor behavior and drug resistance. The current results remain in the experimental research phase.